1. Home
  2. BNRG vs GNPX Comparison

BNRG vs GNPX Comparison

Compare BNRG & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brenmiller Energy Ltd

BNRG

Brenmiller Energy Ltd

HOLD

Current Price

$0.82

Market Cap

4.7M

Sector

N/A

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.77

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNRG
GNPX
Founded
2012
2009
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
4.2M
IPO Year
2022
2018

Fundamental Metrics

Financial Performance
Metric
BNRG
GNPX
Price
$0.82
$1.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
134.3K
274.0K
Earning Date
09-30-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$387,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
843.90
N/A
52 Week Low
$0.61
$1.75
52 Week High
$15.30
$55.00

Technical Indicators

Market Signals
Indicator
BNRG
GNPX
Relative Strength Index (RSI) 42.76 30.92
Support Level $0.63 $2.51
Resistance Level $0.93 $3.68
Average True Range (ATR) 0.10 0.22
MACD 0.01 -0.07
Stochastic Oscillator 41.05 2.93

Price Performance

Historical Comparison
BNRG
GNPX

About BNRG Brenmiller Energy Ltd

Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: